Faced with bans on some of its key drugmakers and intellectual property fights with Big Pharma, India has seen the worst pharma export numbers in a decade and a half.
Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.
With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.
Catalent has signed a deal to lend its biologics development technology to China's Zhejiang Hisun Pharmaceuticals and help the drugmaker get working on copies of some top-selling drugs.
Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.
Its deal for Arab Pharmaceutical Product Company (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics.
As growth has slowed in some emerging markets, Western drugmakers are looking to second- and third-tier emerging markets to gain momentum. The Middle East has become the new hot spot for pharma, and AbbVie has found its way there.
As part of its strategy to sell more products in foreign markets, Boston Scientific announced the signing of a distribution partnership agreement allowing Israel's Amos Gazit Ltd to market and sell its interventional cardiology, peripheral interventions, endoscopy and urology/women's health products.
BVCF, a Shanghai-based life sciences investor, has closed its third fund with $188 million to back upstart biotechs on both sides of the Pacific focused on the booming Asian market.
Boston Scientific has launched its much-hyped S-ICD in Asia, notching the first implant of the under-the-skin system in Hong Kong as it looks to expand the market for the device.